AI-generated summary
The authors report a randomised, placebo-controlled trial in 46 head and neck cancer patients receiving radiotherapy, comparing photobiomodulation with placebo to prevent acute radiation dermatitis. They report that photobiomodulation significantly reduced grade 2-3 dermatitis by 49% at the end of radiotherapy, and describe it as the first such randomised trial in this group.
- Participants
- 46
- Who or what was studied
- Head and neck cancer patients undergoing radiotherapy with or without concomitant chemotherapy
- Limits stated in the abstract
- The abstract does not state the wavelengths used or report details of the outcome measures beyond the summary result.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Randomized controlled trial, Placebo-controlled, GRADE. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.